Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	1/28/2005 12:09:27 PM
	Read Replies (1) of 625

Friday January 28, 11:53 AM EST LONDON -(Dow Jones)- UK biotechnology company Cambridge Antibody Technology Group PLC (CATG) Friday was awarded costs in its legal case against Abbott Laboratories Inc (ABT) over the level of royalties for rheumatoid arthritis drug Humira. The amount of the costs will be determined in a separate proceeding. Justice Laddie, referring to Humira, said that this is the first significant exploitation of a breakthrough technology for which Cambridge Antibody is responsible. As a result, he ruled that it's appropriate the company receives adequate compensation for the expenses it incurred in the case. Abbott Laboratories and Cambridge Antibody could not be immediately reached for comment. -By Elena Berton, Dow Jones Newswires; 44 20 7842 9267; elena.berton@ dowjones.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next